Effects of a pressure surround on the regional taste detection threshold for sodium chloride.

The question as to whether tactile stimulation alters proximal taste function in humans has never been answered, despite the suggestion of anatomical and physiological associations between somatosensory and gustatory function in a number of species. In this study, we established NaCl detection thresholds for a 25 mm2 anterior tongue region on four test occasions in each of 12 men and 12 women. Testing was performed using the Regional Automated Taste Testing System (RATTS), a device that allows for accurate temporal and spatial presentation of tastants to the lingual surface. On each test occasion, a different negative pressure (vacuum suction) was applied around the stimulus presentation field of the glass stimulation device (i.e. 40, 50, 60 and 70 mmHg). The order of presentation of the vacua was systematically counterbalanced among subjects across sessions using 4 x 4 Latin square sequences. Neither the vacua nor their order of presentation meaningfully altered the taste threshold values, even though the higher vacua produced persistent discernible discomfort in most subjects. On average, taste thresholds tended to be marginally lower in women than in men. These data indicate that static vacuum-induced tactile stimulation around a discrete anterior taste field has no meaningful influence on NaCl detection threshold sensitivity.

A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis.

An open-label, non-comparative study was performed in three Otolaryngology centers in Bangkok, Thailand, to assess the efficacy, safety and tolerability of fexofenadine in Thai patients with perennial allergic rhinitis. Altogether 101 perennial allergic rhinitis patients were included, 33 males and 68 females. Mean age was 33 years, average duration of symptoms was 6 years. All patients received fexofenadine hydrochloride 120 mg once daily (OD) in the morning for 2 weeks. Patients recorded their allergy symptoms daily using a 5 point rating scales in the diary card. At the end of 2 weeks, patients and investigators assessed the overall efficacy of treatment. Adverse events and onset of symptom relief were also recorded by every patient. Blood test and ECG were performed before and after treatment in one center (Siriraj Hospital). Total symptom scores and nasal scores decreased significantly from a baseline at 1 week and 2 weeks after treatment (p < 0.05). The mean onset of symptom relief was 2 hours and 12 minutes. The global assessment of the treatment by patients and investigators showed significant concordance. There was no significant change in either the vital signs, laboratory tests or ECG. The incidence of treatment related adverse events was 8% but all were mild and easily tolerated. Drowsiness was reported from only one patient. This study suggests that fexofenadine 120 mg once daily was an effective, safe and well tolerated treatment for perennial allergic rhinitis in Thai patients.